Stifel is serving as exclusive financial advisor to Minghui
PR Newswire news releases · 2026-11-04 14:30
查看证据
- 公司披露PR Newswire news releases2026-11-04 14:30
Stifel is serving as exclusive financial advisor to Minghui
查看来源
公司
公司
第 15082 位,共 118934 个前 13%本周下降 7912 位
3 条直接关系
所在群组共 78 个紧密关联的对象,核心是
按有证据的公开关系计算,每天更新。
箭头表示关系方向,可按业务类别筛选。
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.查看来源
Stifel is serving as exclusive financial advisor to Minghui查看来源
Fangda Partners is serving as legal advisor.查看来源
显示第 1 至 3 条,共 3 条
结合来源阅读结论,展开条目查看证据。
Stifel is serving as exclusive financial advisor to Minghui
PR Newswire news releases · 2026-11-04 14:30
Stifel is serving as exclusive financial advisor to Minghui查看来源
Fangda Partners is serving as legal advisor.
PR Newswire news releases · 2026-11-04 14:30
Fangda Partners is serving as legal advisor.查看来源
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.
PR Newswire news releases · 2026-11-04 14:30
Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") today announced that they have entered into an exclusive license agreement for the development and commercialization of MHB018A in Japan.查看来源
Minghui will receive an upfront payment of USD 110 million
PR Newswire news releases · 2026-11-04 14:30
Minghui will receive an upfront payment of USD 110 million查看来源
as well as tiered royalties up to mid-30% on net sales in Japan.
PR Newswire news releases · 2026-11-04 14:30
as well as tiered royalties up to mid-30% on net sales in Japan.查看来源
显示第 1 至 5 条,共 5 条
估值数据需要 Pro 或 Research。
升级到 Pro 解锁这家公司有哪些页面值得盯着,比如价格、更新日志、条款或招聘页?推荐给我们。每条推荐都有人看;收录后,这个页面会为所有读者一起监测,并且只有连续两次抓取一致才算一次变化。
暂无: 公司信号 · 财务数据 · 披露文件 · 据点 · 业绩指引